Onishi Masaya, Ochiya Takahiro, Tanaka Yasuhito
Department of Virology & Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan.
Department of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical University, Tokyo 160-8402, Japan.
Cancer Drug Resist. 2020 Apr 17;3(3):385-400. doi: 10.20517/cdr.2019.110. eCollection 2020.
Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths worldwide. HCC is characterized by a poor prognosis and an ever increasing number of scientific studies aim to find new diagnostic, prognostic, and therapeutic targets. MicroRNAs (miRNAs), small non-coding RNAs that regulate the gene expression in many processes, have been shown to play a crucial role in regulating hepatocellular carcinoma. miRNAs may act as oncogenic miRNAs and tumor suppressor miRNAs and regulate cancer cell proliferation, invasion, and metastasis by being differently upregulated or downregulated and targeting the genes related with carcinogenesis. miRNAs secreted from cancer cells are found circulating in the blood, presenting an opportunity for their use as disease-related biomarkers. Moreover, extracellular vesicle-derived miRNAs are known to reflect the cell of origin and function and may provide effective biomarkers for predicting diagnosis and prognosis and new therapeutic target in HCC. In this article, we describe the most recent findings regarding the molecular mechanisms and gene regulation of microRNA in HCC, as well as their application in diagnosis/prognosis and treatment.
肝细胞癌(HCC)是全球癌症相关死亡的主要原因。HCC的特点是预后较差,越来越多的科学研究旨在寻找新的诊断、预后和治疗靶点。微小RNA(miRNA)是在许多过程中调节基因表达的小型非编码RNA,已被证明在调节肝细胞癌中起关键作用。miRNA可作为致癌miRNA和肿瘤抑制miRNA,并通过不同程度的上调或下调以及靶向与致癌作用相关的基因来调节癌细胞的增殖、侵袭和转移。在血液中发现癌细胞分泌的miRNA循环存在,这为将其用作疾病相关生物标志物提供了机会。此外,已知细胞外囊泡衍生的miRNA反映细胞来源和功能,并可能为预测肝细胞癌的诊断和预后提供有效的生物标志物以及新的治疗靶点。在本文中,我们描述了关于miRNA在肝细胞癌中的分子机制和基因调控的最新发现,以及它们在诊断/预后和治疗中的应用。